In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term outcomes thwarted by repeated cycles of relapse and remission. This is ...

每经AI快讯，1月9日，据赛诺菲中国微信公众号消息，赛诺菲今日宣布，旗下抗CD38单抗赛可益（艾沙妥昔单抗注射液）获得国家药品监督管理局（NMPA ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

The therapy works by reprogramming a patient's T-cells with a transgene encoding a CAR that identifies and eliminates cells that express the B-cell maturation ... a PI and an anti-CD38 monoclonal ...